首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation
【24h】

Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation

机译:包含稳定的高分子量和低分子量透明质酸杂合合作配合物的可注射医疗器械的功效和耐受性:单中心16周开放标签评估

获取原文
       

摘要

Background: An injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid (HA) has been developed with characteristics suited for a global improvement of facial esthetics. Objective: To evaluate the HA product performance in improving some key facial esthetic features. The study employed clinical scales, subjective evaluations, and facial skin objective measurements. Methods: A single Italian site treated 64 female subjects aged 38–60 years, with injections at five predetermined points, on each side of the face, with a 4-week time lapse between the first and the second product administration. Subjects were evaluated after 4, 8, 12, and 16 weeks, using validated clinical scales, subjective evaluation, and objective quantitative outcome measures. Assessment of esthetic results included photographic documentation. Results: Both the clinical and subjective assessments, and the majority of objective instrumental parameters indicated an improvement throughout the study and were already significant at week 4 or 8 and were still significant at week 16 (3 months after the second treatment). Minor and temporary local skin reactions were observed in 23% of subjects at the site of the injections, and the global judgment on tolerability was good or excellent, both in the investigators’ opinion and volunteers’ self-evaluation. Conclusion: Both subjective and objective improvement of the facial parameters was consistent with the bio-remodeling purpose, and persistent and still statistically significant at the end of the study. The tolerability and safety profile of the product were judged good or excellent both by investigators and volunteers. This study supports the claim for bio-remodeling of these stable hybrid cooperative complexes of low- and high-molecular-weight HA.
机译:背景:已经开发出一种包含高分子量和低分子量透明质酸(HA)的稳定杂合合作配合物的可注射医疗设备,其特征适合于全面改善面部美学。目的:评估HA产品在改善某些关键的面部美学特征方面的性能。该研究采用临床量表,主观评估和面部皮肤客观测量。方法:在一个意大利站点上治疗了64位年龄在38至60岁之间的女性受试者,在面部的每个侧面上的五个预定点进行了注射,从第一次给药到第二次给药之间间隔了4周的时间。在第4、8、12和16周后使用有效的临床量表,主观评估和客观的定量结局指标对受试者进行评估。审美结果的评估包括摄影文件。结果:临床和主观评估以及大多数客观仪器参数均表明整个研究过程均有改善,并且在第4周或第8周时已经显着,在第16周时(第二次治疗后3个月)仍然显着。在研究人员的意见和志愿者的自我评价中,在注射部位的23%的受试者中均观察到了轻微和暂时的局部皮肤反应,对耐受性的总体判断是好还是极好。结论:面部参数的主观和客观改善均与生物重塑目的相符,并且在研究结束时持续存在并仍具有统计学意义。研究人员和志愿者都认为产品的耐受性和安全性是好还是不好。这项研究支持对这些低分子量和高分子量HA稳定的杂合合作复合物进行生物重塑的主张。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号